Andrew Cheng - 03 Jan 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
03 Jan 2023
Net transactions value
-$1,266,376
Form type
4
Filing time
05 Jan 2023, 17:46:29 UTC
Previous filing
20 Dec 2022
Next filing
03 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $15,375 +25,000 +6.7% $0.6150* 395,999 03 Jan 2023 Direct F1
transaction AKRO Common Stock Sale $661,583 -13,200 -3.3% $50.12 382,799 03 Jan 2023 Direct F1, F2
transaction AKRO Common Stock Sale $193,114 -3,800 -0.99% $50.82 378,999 03 Jan 2023 Direct F1, F3
transaction AKRO Common Stock Sale $156,096 -3,000 -0.79% $52.03 375,999 03 Jan 2023 Direct F1, F4
transaction AKRO Common Stock Sale $42,470 -800 -0.21% $53.09 375,199 03 Jan 2023 Direct F1, F5
transaction AKRO Common Stock Sale $212,047 -3,900 -1% $54.37 371,299 03 Jan 2023 Direct F1, F6
transaction AKRO Common Stock Sale $16,442 -300 -0.08% $54.81 370,999 03 Jan 2023 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -25,000 -12% $0.000000 185,868 03 Jan 2023 Common Stock 25,000 $0.6150 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.52 to $50.51, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.53 to $51.38, inclusive.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $51.55 to $52.50, inclusive.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $52.57 to $53.37, inclusive.
F6 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.74 to $54.61, inclusive.
F7 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.80 to $54.81, inclusive.
F8 The options are vested and currently exercisable.